Targeting DNA Damage Repair Mechanisms in Pancreas Cancer.
| العنوان: | Targeting DNA Damage Repair Mechanisms in Pancreas Cancer. |
|---|---|
| المؤلفون: | Perkhofer L; Department of Internal Medicine I, Ulm University Hospital, 89081 Ulm, Germany., Golan T; Oncology Institute, Sheba Medical Center, Tel Aviv University, Tel Aviv 52621, Israel., Cuyle PJ; Digestive Oncology Department, Imelda General Hospital, 2820 Bonheiden, Belgium.; University Hospitals Gasthuisberg Leuven and KU Leuven, 3000 Leuven, Belgium., Matysiak-Budnik T; IMAD, Department of Gastroenterology and Digestive Oncology, Hôtel Dieu, CHU de Nantes, 44000 Nantes, France., Van Laethem JL; GI Cancer Unit, Erasme Hospital, Université Libre de Bruxelles, 1070 Brussels, Belgium., Macarulla T; Vall d'Hebrón University Hospital and Vall d'Hebron Institute of Oncology, 08035 Barcelona, Spain., Cauchin E; IMAD, Department of Gastroenterology and Digestive Oncology, Hôtel Dieu, CHU de Nantes, 44000 Nantes, France., Kleger A; Department of Internal Medicine I, Ulm University Hospital, 89081 Ulm, Germany., Beutel AK; Department of Internal Medicine I, Ulm University Hospital, 89081 Ulm, Germany., Gout J; Department of Internal Medicine I, Ulm University Hospital, 89081 Ulm, Germany., Stenzinger A; Institute of Pathology, University Hospital Heidelberg, 69120 Heidelberg, Germany., Van Cutsem E; University Hospitals Gasthuisberg Leuven and KU Leuven, 3000 Leuven, Belgium., Bellmunt J; Medical Oncology, University Hospital del Mar, 08003 Barcelona, Spain.; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA., Hammel P; Hôpital Beaujon, 92110 Clichy, France., O'Reilly EM; Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.; Department of Medicine, David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA., Seufferlein T; Department of Internal Medicine I, Ulm University Hospital, 89081 Ulm, Germany. |
| المصدر: | Cancers [Cancers (Basel)] 2021 Aug 24; Vol. 13 (17). Date of Electronic Publication: 2021 Aug 24. |
| نوع المنشور: | Congress |
| اللغة: | English |
| بيانات الدورية: | Publisher: MDPI Country of Publication: Switzerland NLM ID: 101526829 Publication Model: Electronic Cited Medium: Print ISSN: 2072-6694 (Print) Linking ISSN: 20726694 NLM ISO Abbreviation: Cancers (Basel) Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: Basel, Switzerland : MDPI |
| مستخلص: | Impaired DNA damage repair (DDR) is increasingly recognised as a hallmark in pancreatic ductal adenocarcinoma (PDAC). It is estimated that around 14% of human PDACs harbour mutations in genes involved in DDR, including, amongst others, BRCA1/2 , PALB2 , ATM , MSH2 , MSH6 and MLH1 . Recently, DDR intervention by PARP inhibitor therapy has demonstrated effectiveness in germline BRCA1/2 -mutated PDAC. Extending this outcome to the significant proportion of human PDACs with somatic or germline mutations in DDR genes beyond BRCA1/2 might be beneficial, but there is a lack of data, and consequently, no clear recommendations are provided in the field. Therefore, an expert panel was invited by the European Society of Digestive Oncology (ESDO) to assess the current knowledge and significance of DDR as a target in PDAC treatment. The aim of this virtual, international expert meeting was to elaborate a set of consensus recommendations on testing, diagnosis and treatment of PDAC patients with alterations in DDR pathways. Ahead of the meeting, experts completed a 27-question survey evaluating the key issues. The final recommendations herein should aid in facilitating clinical practice decisions on the management of DDR-deficient PDAC. |
| References: | Cancer Epidemiol Biomarkers Prev. 2011 Apr;20(4):691-8. (PMID: 21278327) JCO Precis Oncol. 2018;2018:. (PMID: 30051098) Cancer Res. 2012 Nov 1;72(21):5454-62. (PMID: 22933060) Cold Spring Harb Perspect Biol. 2013 Nov 01;5(11):a012740. (PMID: 24097900) CA Cancer J Clin. 2020 Jan;70(1):7-30. (PMID: 31912902) J Clin Oncol. 2020 May 1;38(13):1442-1454. (PMID: 32073954) JAMA Oncol. 2017 Jun 01;3(6):774-783. (PMID: 27768182) Clin Cancer Res. 2018 Mar 15;24(6):1326-1336. (PMID: 29367431) Nature. 2020 May;581(7806):100-105. (PMID: 32376951) JAMA Oncol. 2021 May 01;7(5):693-699. (PMID: 33662100) Science. 2008 Sep 26;321(5897):1801-6. (PMID: 18772397) J Clin Oncol. 2017 Oct 20;35(30):3382-3390. (PMID: 28767289) Genet Med. 2015 Jul;17(7):569-77. (PMID: 25356972) Br J Cancer. 2012 Dec 4;107(12):2005-9. (PMID: 23099806) Br J Cancer. 2017 Mar 14;116(6):697-702. (PMID: 28183138) Gastroenterology. 2021 May;160(6):2119-2132.e9. (PMID: 33524400) Nature. 2015 Feb 26;518(7540):495-501. (PMID: 25719666) Clin Cancer Res. 2017 Jun 15;23(12):3097-3108. (PMID: 27993965) Nat Commun. 2015 Jul 29;6:7677. (PMID: 26220524) Genes Dev. 2017 Feb 1;31(3):318-332. (PMID: 28242626) J Natl Compr Canc Netw. 2020 Apr;18(4):380-391. (PMID: 32259785) Gut. 2021 Apr;70(4):743-760. (PMID: 32873698) JCO Precis Oncol. 2019 Dec;3:1-10. (PMID: 35100730) JCO Precis Oncol. 2019 Dec;3:1-11. (PMID: 35100679) Cold Spring Harb Mol Case Stud. 2017 Nov 21;3(6):. (PMID: 29162654) Gut. 2021 Mar;70(3):606-617. (PMID: 32855305) Cancer Res. 2014 Jun 1;74(11):2913-21. (PMID: 24840647) Trends Cell Biol. 2019 Sep;29(9):740-751. (PMID: 31362850) JAMA Netw Open. 2020 Oct 1;3(10):e2019452. (PMID: 33026450) Genet Med. 2015 May;17(5):405-24. (PMID: 25741868) Cancer. 2012 Jan 15;118(2):493-9. (PMID: 21598239) Ann Oncol. 2015 Sep;26 Suppl 5:v56-68. (PMID: 26314780) JAMA. 2017 Sep 5;318(9):825-835. (PMID: 28873162) Ann Surg Oncol. 2020 Oct;27(10):3963-3970. (PMID: 32314163) Nature. 2019 Jul;571(7766):576-579. (PMID: 31292550) Anticancer Res. 2014 Jan;34(1):471-6. (PMID: 24403503) N Engl J Med. 2019 Jul 25;381(4):317-327. (PMID: 31157963) JAMA Oncol. 2020 May 1;6(5):764-771. (PMID: 32053139) Genet Med. 2019 Jan;21(1):213-223. (PMID: 29961768) JAMA. 2018 Jun 19;319(23):2401-2409. (PMID: 29922827) Clin Cancer Res. 2014 Feb 1;20(3):540-7. (PMID: 24270682) Clin Cancer Res. 2020 Jul 1;26(13):3239-3247. (PMID: 32444418) J Clin Oncol. 2015 Oct 1;33(28):3124-9. (PMID: 25940717) Clin Cancer Res. 2020 Jun 1;26(11):2704-2710. (PMID: 31796517) Cancer. 2015 Dec 15;121(24):4382-8. (PMID: 26440929) Cancer Discov. 2012 Apr;2(4):366-375. (PMID: 22576213) Cancer Discov. 2016 Feb;6(2):166-75. (PMID: 26658419) Clin Cancer Res. 2020 Aug 1;26(15):4135-4142. (PMID: 32332016) Cancer Res. 2017 Oct 15;77(20):5576-5590. (PMID: 28790064) Br J Cancer. 2014 Sep 9;111(6):1132-8. (PMID: 25072261) Gastroenterology. 2019 Jun;156(8):2242-2253.e4. (PMID: 30836094) J Clin Oncol. 2020 May 1;38(13):1378-1388. (PMID: 31976786) Ann Oncol. 2020 Jul;31(7):861-872. (PMID: 32272210) Ann Oncol. 2020 Dec;31(12):1606-1622. (PMID: 33004253) |
| معلومات مُعتمدة: | P30 CA008748 United States CA NCI NIH HHS |
| فهرسة مساهمة: | Keywords: BRCA1/2; DNA damage repair; PARP inhibition; homologous repair deficiency; pancreatic ductal adenocarcinoma; platinum |
| تواريخ الأحداث: | Date Created: 20210910 Latest Revision: 20240403 |
| رمز التحديث: | 20240403 |
| مُعرف محوري في PubMed: | PMC8428219 |
| DOI: | 10.3390/cancers13174259 |
| PMID: | 34503069 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 2072-6694 |
|---|---|
| DOI: | 10.3390/cancers13174259 |